Thursday, May 6, 2021 Daily Archives

Fill & finish investments plus pandemic drive Catalent’s biologics biz

by and

Biologics now represent over half of Catalent’s revenues with the firm citing drug product manufacture as a major driver. For a number of years, contract development manufacturing organization (CDMO) Catalent has been tipping the balance of its business away from its small molecule and delivery technology heritage, and towards its biologics business. The biologics business pulled in around 32% of Catalent’s business mix in 2019, but in under two years the division pulled in over half of the CDMO’s net revenues…

May 6, 2021

Eppendorf $100m of capacity expansions reflects record year

by

Eppendorf says it will continue investing in production capabilities and infrastructure as it reports a record 12 months. German life sciences tool provider Eppendorf reported revenues of €967 million($1.16 billion) for its fiscal year 2020, up 20.3% on the year prior. “2020 was by far the most successful fiscal year for the Eppendorf Group,†co-CEOs Eva van Pelt and Peter Fruhstorfer said in a joint statement. Like many of its fellow bioprocess suppliers, growth in sales across many of Eppendorf’s…

May 6, 2021

Survey highlights lack of minority leadership in life science space

by

The lack of ethnic minorities and women in leadership roles is the biggest problem with diversity and inclusion in the life sciences space, according to a survey from Informa Connect. Over 480 people working across the life sciences space responded to a survey entitled ‘Diversity, Equity and Inclusion in the Life Sciences 2021,’ conducted by Informa Connect in March, and the results are now in. While respondents stressed that a combination of many problems plagued our industry, over a third…

May 6, 2021